3 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Diverticulitis: new trials by email Literature Review of Diverticulitis trials Research Report on Diverticulitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. Rifaximin delayed released 400mg Tablet, Placebo - Diverticulitis | Phase 2 / Phase 3 | Terminated | Alfasigma S.p.A. | 193 | 2018-07-02 | 2021-10-20 |
| Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis Mesalazine, Placebo - Diverticulitis | Phase 3 | Terminated | Dr. Falk Pharma GmbH | 330 | 2010-01-01 | 2017-07-21 |
| Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis Mesalazine, Placebo - Diverticulitis | Phase 3 | Terminated | Dr. Falk Pharma GmbH | 345 | 2008-01-01 | 2017-07-24 |
Digestive System Diseases (3) · Diverticular Diseases (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3)
Mesalamine (2) · Tablets (1)
Dr. Falk Pharma GmbH (2) · Alfasigma S.p.A. (1)
Germany (2) · France (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)
PMID 28543263, PMID 28707787, PMID 28707796
2009 (1), 2017 (1)